Role of Host Xanthine Oxidase in Infection Due to Enteropathogenic and Shiga-Toxigenic *Escherichia coli*

John K. Crane,† Tonniele M. Naheer,** Jacqueline E. Broome,† Edgar C. Boedeke†

Department of Medicine, Division of Infectious Diseases, University at Buffalo, Buffalo, New York, USA; Department of Medicine, Division of Gastroenterology, University of New Mexico, Albuquerque, New Mexico, USA

Xanthine oxidase (XO), also known as xanthine oxidoreductase, has long been considered an important host defense molecule in the intestine and in breastfed infants. Here, we present evidence that XO is released from and active in intestinal tissues and fluids in response to infection with enteropathogenic *Escherichia coli* (EPEC) and Shiga-toxigenic *E. coli* (STEC), also known as enterohemorrhagic *E. coli* (EHEC). XO is released into intestinal fluids in EPEC and STEC infection in a rabbit animal model. XO activity results in the generation of surprisingly high concentrations of uric acid in both cultured cell and animal models of infection. Hydrogen peroxide (H$_2$O$_2$) generated by XO activity triggered a chloride secretory response in intestinal cell monolayers within minutes but decreased transepithelial electrical resistance at 6 to 22 h. H$_2$O$_2$ generated by XO activity was effective at killing laboratory strains of *E. coli*, commensal microbiotas, and anaerobes, but wild-type EPEC and STEC strains were 100 to 1,000 times more resistant to killing or growth inhibition by this pathway. Instead of killing pathogenic bacteria, physiologic concentrations of XO increased virulence by inducing the production of Shiga toxins from STEC strains. *In vivo*, exogenous XO plus the substrate hypoxanthine did not protect and instead worsened the outcome of STEC infection in the rabbit ligated intestinal loop model of infection. XO released during EPEC and STEC infection may serve as a virulence-inducing signal to the pathogen and not solely as a protective host defense.

**MATERIALS AND METHODS**

**Bacterial strains used.** Bacterial strains used are shown in Table 1. Xanthine oxidase, hypoxanthine, uric acid, allopurinol, and oxypurinol were purchased from Sigma (St. Louis, MO). Uricase was from Worthington Biochemicals (Freehold, NJ).

**T84 cell culture.** T84 cells were grown as previously described (7).

Received 12 October 2012 Returned for modification 21 November 2012 Accepted 18 January 2013 Published ahead of print 22 January 2013

Editor: B. A. McCormick

Address correspondence to John K. Crane, jcrane@buffalo.edu.

* Present address: Tonniele M. Naheer, Academic Software Plus, Science, Office of Technology Transfer and Economic Outreach, Amherst, New York, USA.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/IAI.01124-12
Uric acid assay. Uric acid was measured using a kit from Bioassay Systems, Inc. (Hayward, CA), according to the instructions of the manufacturer. As recommended in the instructions, samples were subjected to filtration through a 10,000 molecular weight (MW) cutoff (10K MWCO) filter before assay. Spin Filter 10K filters were from VWR (Radnor, PA). This step was helpful in removing hemoglobin from bloody samples, such as loop fluids. Uric acid concentrations in mg/dl were converted to micromolar units (μM/liter) by multiplying by 59.5. Uric acid concentrations are shown in units of μM/liter or mg/liter.

Xanthine oxidase assay. XO activity was measured by monitoring the conversion of hypoxanthine to uric acid as described previously (8) except that uric acid was measured using the kit method described previously rather than by UV spectrometry. However, most of the loop fluid samples already contained uric acid before the assay even began. Therefore, uric acid production was calculated as the increase in uric acid between the diluted sample incubated with hypoxanthine and the same sample incubated without hypoxanthine. This difference was termed the [uric acid]. Standard conditions were to dilute the sample 3-fold in HEPES-buffered saline and then incubate with and without hypoxanthine substrate at 37°C for 3 h with 600-rpm shaking on a BioShake iQ heater block (Bulldog Bio, Portsmouth, NH). Incubations were done in the top chamber of 10K MWCO filters fitted in Eppendorf tubes. The reaction was terminated by centrifugation at 16,000 g in a desktop centrifuge for 5 min and then assaying the filtrate for uric acid. We tested whether adding NADH would increase the apparent enzyme activity and found that in most cases it did not, although it occasionally produced a 10 to 20% increase in uric acid production. We assumed, therefore, that the loop fluids also contain enough NADH for the reaction to proceed.

Assays for inhibition of bacterial growth. Effects of XO on bacterial growth were calculated by measuring turbidity, measured as the optical density at 600 nm (OD600), in 96-well plates incubated at 37°C. Growth assays were done in LB, Dulbecco’s modified Eagle medium (DMEM), or minimal medium. In this study, minimal medium was defined as M9 salts plus 2% Casamino acids and 2 mM glucose. Bacteria for the assay were grown overnight in LB medium and then diluted 1:100 into the wells of the 96-well plate. Hypoxanthine and/or XO was added immediately, and growth was measured at various time intervals. In more-recent experiments, we have begun covering the plates with sterile, gas-permeable sealer film and shaking at 600 rpm on the BioShake iQ shaker/heater block.

Ussing chamber measurements of chloride secretion. Ussing chamber measurements of chloride secretion, measured as short-circuit current, were as previously described (9). T84 cells for Ussing chamber experiments were grown on 12-mm Snap-Well inserts (Corning Costar, Corning, NY).

Measurements of transepithelial electrical resistance. TER was measured on polarized T84 cells grown to confluence on 12-mm Transwell inserts with a 3.0-μm pore size. TER was measured using an Evom2 in-

![Biochemical reactions in the pathway for catabolism of nucleosides and purines. Uricase is absent in humans, great apes, and Dalmatian dogs but present in other mammals and birds, as well as many microbes.](http://iai.asm.org/)

**FIG 1**

| TABLE 1 Bacterial strains used |
|--------------------------------|
| Strain group and name | Serotype<sup>a</sup> | Comment | Reference |
|------------------------|-----------------------|---------|----------|
| **EPEC strains** | | | |
| E2348/69 | O127:H6 | Classic or typical wild-type EPEC | 37 |
| JCP88 | O119:B14 | Classic or typical wild-type EPEC | 38 |
| B171-8 | O111:NM | Classic or typical wild-type EPEC | 39 |
| JPN15 | | EAF(−); plasmid-cured derivative of E2348/69 | 40 |
| **Commensal and laboratory E. coli strains** | | | |
| HS | O9:H4 | Normal commensal E. coli | 37 |
| DH5α | —; K-12 | Laboratory E. coli strain | 41 |
| **Human STEC strains** | | | |
| Popeye-1 | O157:H7 | U.S. spinach-associated outbreak strain, Stx2 only; Stx2a, Stx2c | 6 |
| EDL933 | O157:H7 | Stx1<sup>−</sup>, Stx2<sup>+</sup> | 42 |
| **Rabbit strains** | | | |
| E2 | O103:H2 | Virulent rabbit EPEC strain | 43 |
| E22-stx2 | O103:H2 | E22 transduced with phage 933W encoding Stx2 | 6 |
| **Anaerobes** | | | |
| Bacteroides fragilis | NA | Clinical isolate, bloodstream, Erie County Medical Center | |
| Bacteroides thetaiotaomicron | NA | Microbiologics, St. Cloud, MN | ATCC 29741 |

<sup>a</sup> —, no O serotype because the strain lacks O antigens; NA, not applicable.
Xanthine Oxidase, EPEC, and STEC

April 2013 Volume 81 Number 4  iai.asm.org

FIG 2 Release of uric acid into supernatant medium of cultured T84 cells in response to EPEC infection. (A) Comparison of uric acid release between commensal E. coli strain HS, wild-type EPEC strain E2348/69, and the plasmid-cured derivative of E2348/69, JPN15. *, significantly greater than JPN15. (B) Effect of increasing multiplicity of infection (MOI) on uric acid released from cultured T84 monolayers by infection with Salmonella enterica serotype Enteritidis, EPEC JCP88, and E. coli HS. (C) Effect of the xanthine oxidase inhibitors allopurinol and oxypurinol on EPEC-induced uric acid release from T84 cells. *, significantly increased compared to the uninfected control; **, significantly decreased compared to JCP88 without allopurinol. uninf, uninfected.

In previous work, we observed that EPEC infection resulted in the release of adenosine into the intestinal lumen at concentrations up to 30 to 40 μM in rabbits (11). We wondered if adenosine was the end of the line metabolically or if nuleoside catabolism continued further with production of inosine or other metabolites (Fig. 1). While trying to develop assays for inosine, we were surprised to find that high levels of uric acid were readily detectable in the supernatants of cultured cells infected with EPEC (Fig. 2).

Figure 2A shows that in response to infection with EPEC E2348/69, uric acid levels in the supernatant medium rose to ~200 μM concentrations within 6 h of infection. The plasmid-cured derivative of that strain, JPN15, which is defective in adherence and ability to inflict host cell damage, showed significantly less uric acid release, as did the normal commensal E. coli strain HS. Figure 2B shows that the uric acid release increased with increasing multiplicity of infection (MOI) for EPEC (strain JCP88) as well as for Salmonella enterica serotype Enteritidis. E. coli HS failed to release much uric acid even at high MOIs. We also observed that infection with Aeromonas hydrophila or treatment of cells with A. hydrophila culture supernatants containing aerolysin also released uric acid from host cells at levels similar to those for S. enterica (data not shown). A. hydrophila was tested because Fujii et al. had previously shown that this pathogen also releases ATP from host cells (12).

Figure 2C shows that the EPEC-induced uric acid release was inhibited by allopurinol, showing that the catalytic activity of xanthine oxidase was involved in the uric acid generation. Oxypurinol also inhibited uric acid with potency similar to that of allopurinol (data not shown).

To further pursue the findings shown in Fig. 2, we assayed uric acid levels in the intestinal loop fluid recovered from rabbits infected with EPEC. In this model, 10-cm loops of ileum are ligated and then infected by injection of bacteria directly into the loop. A
total of 20 h later, the loop fluids are recovered and analyzed. Figure 3A shows that uric acid concentrations were significantly higher in loops infected with EPEC than in neighboring loops from the same animal that were left uninfected (buffered saline control). We also measured uric acid in serum of non-surgically altered rabbits infected orally with rabbit EPEC strain E22 and found that serum uric acid levels rose significantly 7 days postinfection compared to serum from the same rabbit before infection (Fig. 3B). The rise in uric acid in serum suggests that some of the uric acid produced in the intestine may be carried away by the bloodstream; therefore, the rise in uric acid in the loop fluid (Fig. 3A) may underestimate the true extent of uric acid production. The results of Fig. 3A and B indicated that the rise in uric acid production seen in cultured T84 cells was also observed in an animal model.

Figure 3C shows that in addition to uric acid itself, fluid from infected loops contained XO activity and was able to generate uric acid ex vivo when supplied with hypoxanthine as the substrate. Figure 3C shows XO activity in pairs of uninfected and infected loop fluid from 6 different animals, 3 of which were infected with rabbit EPEC strain E22 and 3 of which were infected with rabbit STEC E22-stx2. None of the uninfected loop fluids contained significant amounts of XO activity; in fact, 5 of 6 uninfected samples actually showed disappearance of uric acid during the assay (i.e., a negative number on the graph). The loss of uric acid in the uninfected rabbit fluids may be the result of the enzyme uricase, which rabbits and most mammals, unlike humans, great apes, and Dalmatian dogs, possess (Fig. 1). Loop fluids from both EPEC-infected and STEC-infected loops contained significant amounts of XO activity, even after cells and debris were removed by centrifugation, sterile filtration, or both. When the XO activity observed in Fig. 3C was calculated in terms of XO activity units (1 unit is the amount of enzyme needed to convert 1 \( \mu \text{mol} \) of hypoxanthine to uric acid per minute), the XO activity was less than 0.01 U/ml of loop fluid, or about one-twentieth of that present in unpasteurized bovine milk (13).

Xanthine oxidase activity generates hydrogen peroxide as well as uric acid (Fig. 1), and the peroxide produced is considered the basis of its antimicrobial properties (2). It seemed counterintuitive that EPEC and STEC would trigger the release of an enzyme, XO, that can produce potentially lethal amounts of \( \text{H}_2\text{O}_2 \). Therefore, we investigated the effects of XO on bacteria.

Figure 4 shows the effects of exogenous XO on bacterial growth and virulence. In pilot experiments, it was difficult to demonstrate bacterial growth inhibition at low concentrations of XO, so the amount of XO was increased to 1 U/ml. In Fig. 4A to C, the XO concentration was held constant (at 1 U/ml) and the concentration of hypoxanthine substrate was varied over a 500-fold range, from 2 \( \mu \text{M} \) to 1,000 \( \mu \text{M} \). Figure 4A shows that no inhibition of EPEC growth was observed with XO plus adenosine or XO plus inosine, but growth was inhibited in the presence of hypoxanthine substrate (see Fig. 1). Figure 4B compares the susceptibilities of 3 \textit{E. coli} strains to growth inhibition by XO plus hypoxanthine. Growth of

XO Activity

![Diagram](http://iai.asm.org/images/3/3a/fig3a.png)

**FIG 3** Release of uric acid and xanthine oxidase activity into intestinal loop fluids and serum after infection of rabbits with EPEC E22 or rabbit STEC E22-stx2. (A) Comparison of the uric acid contents of uninfected and EPEC E22-infected ligated rabbit intestinal loops after a 20-h infection. Each line segment represents the uric acid from an uninfected and an infected intestinal loop fluid from the same animal. (B) Increase in serum uric acid in nonsurgically altered rabbits infected orally with strain E22 for 7 days compared with levels in the same animal preinfection. (C) Detection of xanthine oxidase (XO) activity in intestinal loop fluids from infected, but not uninfected, ligated ileal loops. XO activity of 6 pairs of intestinal loop fluid samples from 6 rabbits. Uninfected and infected loops shown in adjacent bars as pairs of loop fluids are from the same animal. The first 3 pairs on the left show data from experiments in which some loops were infected with EPEC E22, and the pairs on the right side are from 3 animals for which some loops were infected with STEC E22-stx2. Although asterisks are omitted, in each case, the XO activity was significantly higher in the infected loop than in the uninfected loop fluid. In 5 of 6 cases, the uninfected loop fluid XO activity was a negative number, i.e., uric acid was not generated but instead disappeared in the uninfected loop fluids during the assay, presumably due to uricase activity.
the laboratory *E. coli* strain DH5α was inhibited with a 50% inhibitory concentration (IC₅₀) of ~4 μM hypoxanthine, while EPEC strains B171-8 and E2348/69 showed hypoxanthine IC₅₀ of ~50 and 400 μM, respectively. In other words, EPEC E2348/69 was 100 times more resistant to growth inhibition than strain DH5α in this assay. The laboratory *E. coli* strain HB101 behaved like DH5α, and STEC strains EDL933 and Popeye-1 behaved like E2348/69 in this assay (data not shown). Full inhibition of growth in this assay was accompanied by sterilization of the culture, i.e., no regrowth was observed when contents of inhibited wells were subcultured on fresh medium.

EPEC infection *in vivo* is heaviest in the ileum and cecum, and STEC most heavily infects the cecum and colon. Since the cecum and colon are anaerobic environments, we tested the ability of XO plus hypoxanthine to inhibit the growth of the representative anaerobes *Bacteroides fragilis* and *Bacteroides thetaiotaomicron*. Figure 4C shows the results of these growth experiments, carried out in thioglycolate medium under anaerobic conditions. Under these conditions, no growth inhibition of EPEC E2348/69 was observed whatsoever. DH5α was inhibited with a hypoxanthine IC₅₀ of 320 μM, while *B. thetaiotaomicron* was inhibited with a hypoxanthine IC₅₀ of 2 μM, 160 times lower; the growth curve of catalase-posi-
tive *B. fragilis* was similar to that of DH5α. Since E2348/69 growth was not inhibited, no IC₅₀ can be calculated for EPEC from Fig. 4C. However, if we use DH5α as a bridge or benchmark between the aerobic and anaerobic assays (Fig. 4B and C), we can estimate that *B. thetaiotaomicron* is roughly 16,000 times more susceptible to killing by XO and hypoxanthine than is EPEC E2348/69. However, the concentrations of XO and hypoxanthine required for killing of EPEC and STEC in this *in vitro* assay far exceeded what we actually observed in cultured cells or in rabbit loop fluids (Fig. 3C). Based on Fig. 3 and 4, the amount of XO and its substrate actually released in response to EPEC and STEC infection did not appear to be large enough to inhibit EPEC or STEC growth.

Although XO and hypoxanthine levels did not appear sufficient to kill or inhibit growth of EPEC or STEC, we and others (4, 5) have observed strong effects of hydrogen peroxide on Stx production from STEC at peroxide concentrations well below the lethal range. We tested whether XO and hypoxanthine affected Stx production from STEC strains Popeye-1 (Fig. 4D to F) and EDL933 (results were similar and are not shown). Figure 4D shows that hypoxanthine alone did not stimulate Stx2 production and, in fact, inhibited Stx2 release compared to that of the control. In the presence of XO, however, Stx2 production was significantly increased in a dose-dependent manner with increasing hypoxanthine. Figure 4E shows that the addition of either catalase or glutathione (an antioxidant) effectively reversed the induction of Stx2 observed with XO plus hypoxanthine. This is evidence that it is indeed the H₂O₂ being produced by XO that is responsible for the induction of the toxin. Figure 4F shows that XO at levels as low as 0.15 U/ml significantly induced Stx2, but only when hypoxanthine was also added as a reaction substrate. Figure 4D to F show that subinhibitory concentrations of XO and hypoxanthine have strong biological effects on STEC *in vitro*. These effects require the catalytic activity of XO and are mediated via the reaction product of XO, H₂O₂. The results of Fig. 4 show that XO activity generated catalytic activity of XO and are mediated via the reaction product of XO, H₂O₂ and not merely by protein-protein interaction, cell or receptor binding, or other nonenzymatic mechanisms involving XO.

The electrophysiologic effects of XO plus hypoxanthine, shown in Fig. 5A to D, were all at early time points (40 min or less after addition). We also tested whether XO plus hypoxanthine might trigger damage at later times and found that, indeed, XO plus hypoxanthine triggered a large decrease in transepithelial electrical resistance (TER) at 6 h (Fig. 5E). TER is a marker of tight junction integrity and barrier function of the monolayer, and a drop in TER might affect several important functions, including migration of neutrophils and malabsorption of nutrients (16, 17). Figure 5F shows that XO plus hypoxanthine increased translocation of Stx toxin across T84 cell monolayers in the apical-to-basolateral direction. Stx translocation lagged behind the changes in TER so that Stx in the lower chamber continued to increase long after the nadir in resistance, i.e., Stx in the lower chamber increased even after the monolayer began to recover in resistance. At 9 h, the amount of Stx2 measured in the lower chamber in wells treated with XO and hypoxanthine was 7.9% of that added to the upper wells at the beginning of the experiment (Fig. 5F). Stx2 concentrations in the lower wells continued to increase through 22 h, by which time 20.3% of the Stx had reached the lower wells treated with XO and hypoxanthine, compared to undetectable amounts in the control and dimethyl sulfoxide (DMSO) vehicle wells (data not shown). T84 cells are not killed by Stx1 or Stx2 since they do not express the neutral glycolipid Gb3, which is the receptor for the Shiga toxins.

**Figure 4** shows strong effects of XO and hypoxanthine *in vitro* on bacteria, and **Fig. 5** shows effects of XO and hypoxanthine on cultured cells, but we also wished to know if these effects would be observed *in vivo*. **Figure 6** shows the effect of adding exogenous XO with or without hypoxanthine on the outcome of infection with rabbit STEC *in vivo* in the ligated ileal loop assay. **Figure 6A** and B compared the gross appearances of the intestinal loops after 20 h of infection. The loops infected with E22-stx2 alone were distended with fluid but remained normal in appearance (Fig. 6A). **Figure 6B** shows that one of two loops receiving E22-stx2 plus XO and hypoxanthine showed necrotic mottling (left black arrow). **Figure 6C** shows the results of a hemoglobin assay on loop fluids after centrifugation to remove intact cells. Adding XO with STEC reduced the hemoglobin concentrations observed in the fluid, but adding XO and 400 µM hypoxanthine increased the amount of hemoglobin compared to that with STEC and XO. **Figure 6D** shows that...
loops receiving XO or XO plus hypoxanthine along with the pathogen showed a trend toward increased fluid accumulation. Although the increase in loop fluid did not reach statistical significance, the trend appears consistent with the prosecretory effects of XO and hypoxanthine observed in T84 monolayers in Fig. 5. Addition of exogenous XO and hypoxanthine along with STEC also did not diminish the number of pathogenic bacteria recovered from loop fluid at the end of infection (Fig. 6E), consistent

FIG 5  Effects on hypoxanthine plus XO on short-circuit current, electrical resistance, and Stx translocation in polarized T84 cell monolayers studied in the Ussing chamber. Short-circuit current (Isc) represents chloride secretion toward the apical (mucosal or luminal) side of the tissue in this configuration. (A) Comparison of the short-circuit current triggered by 1 mM hypoxanthine plus XO (black tracing) with that triggered by 1 mM H2O2 (gray tracing), showing similar peak currents and similar offsets of secretion. (B) Hypoxanthine alone, without added XO, triggered a very small short-circuit current of ~2 μA/cm2. (C) Dose-response relationship between the amount of hypoxanthine added and the short-circuit current; mean ± standard deviation (SD) of 3 tracings per concentration. (D) Effect of catalase on short-circuit current triggered by hypoxanthine plus XO. When 1,200 U/ml catalase was added simultaneously with hypoxanthine and XO (arrow 1, gray tracing), the secretory response was prevented. When hypoxanthine and XO were added first (black arrow) and a current was allowed to develop, subsequent addition of catalase (2nd black arrow) promptly reversed the secretion. (E) Effect of hypoxanthine (hypo) and XO on transepithelial electrical resistance 6 h after addition of hypoxanthine, XO, or both. * significant decreased compared to the control and to XO alone. (F) Effect of hypoxanthine (hypo) plus XO on Stx translocation across T84 cell monolayers. T84 cells were grown to confluence in Transwell inserts, reaching a mean initial TER value of 1,648 Ω. Hypoxanthine and XO were added to the apical side of the monolayers, followed by Stx2 3 h later. The amount of Stx2 detectable in the lower basolateral chamber was measured at various times after the start of the experiment. *, significant compared to the control, DMSO vehicle, and XO alone.
with the resistance of these bacteria to killing by XO, as shown in Fig. 4. The amount of Stx2 measured in loop fluid at the end of infection, however, was significantly increased by XO and hypoxanthine compared to that with E22-stx2 alone. Again, this is consistent with the increase in Stxs produced by STEC in response to XO and hypoxanthine in Fig. 4D to F. To summarize, the in vivo results in Fig. 6 are consistent with the in vitro data shown in Fig. 4 and 5. In vivo, addition of exogenous XO (to 1 U/ml) plus 400 μM

**FIG 6 Effects of exogenous XO and hypoxanthine on the outcome of STEC infection in a ligated rabbit ileal loop model of infection.** Ten-centimeter segments of ileum were ligated as described in Materials and Methods and infected with $4 \times 10^8$ CFU of rabbit STEC E22-stx2 plus XO and hypoxanthine. Twenty hours after infection, loops were collected and photographed and the contents were analyzed. (A) Gross appearance of an ileal loop infected with E22-stx2 but without any other additives, showing distention with fluid but absence of necrosis. (B) One of 2 intestinal loops receiving E22-stx2 plus XO and hypoxanthine (hypoxnth) showed overt necrotic mottling (loop 6, left arrow), while the other loop showed only one small spot of necrosis at the site of the injection (right arrow). (C) Hemoglobin concentrations in loop fluids were assayed after centrifugation of the samples at 16,000 $\times$ g for 10 min to remove intact cells and debris. In the presence of STEC bacteria, addition of 1 U/ml XO seemed to reduce the bloody character of the loop fluids, but this did not reach statistical significance. *, in the presence of STEC, XO, and 400 μM hypoxanthine, hemoglobin in the loop fluids was significantly higher than that with the pathogen and XO. (D) Fluid secretion into the loops, as measured by the volume-to-length ratio. hypo, hypoxanthine. (E) Comparison of the numbers of bacteria recovered from each loop (expressed as the logarithm of the number of bacteria recovered per loop), showing the lack of any decrease in CFU in loops receiving hypoxanthine (hypo) and XO. (F) Shiga toxin protein (Stx) content of the loops by enzyme immunoassay, expressed in ng per loop. *, significantly increased compared to E22-stx2 alone. hypo, hypoxanthine.
hypoxanthine did not achieve increased antibacterial activity (Fig. 6E) but did result in worsening of infection, including the necrotic gross appearance, bloodier fluid, worsened histology, and increased Stx production in vivo. The findings in Fig. 4 to 6 suggest that for certain resistant pathogens, such as EPEC and STEC, the intestinal xanthine oxidase pathway may not generate sufficient antibacterial activity to inhibit growth of the pathogen. The XO pathway does appear, however, to serve as a signal from the host to the pathogen, enhancing production of Stx and perhaps other virulence traits.

DISCUSSION

Our laboratory has been interested in the role in pathogenesis of the adenine nucleotides, nucleosides, and purines generated from the breakdown of ATP during EPEC and STEC infection (18). While trying to develop assays for adenosine, inosine, and other downstream products of purine catabolism (Fig. 1), we discovered that high concentrations of uric acid were released into the supernatant medium of cultured cells and into the lumen of intestinal loops infected with EPEC (Fig. 2 and 3). This increase in uric acid is not unique to EPEC and STEC, since it is also observed in response to infection with Salmonella enterica (Fig. 2B) and Aeromonas hydrophila (data not shown). The rise in uric acid was also evident in the serum of EPEC-infected rabbits. Palla et al. noted that serum uric acid was elevated in a subset of children with acute gastroenteritis, especially those diagnosed with rotavirus, adenovirus, or Salmonella as the etiology (19, 20). The hyperuricemia persisted even after dehydration had been reversed by rehydration; EPEC and STEC were not tested for in that clinical series. Since that early report, the finding of elevated uric acid levels in rotavirus gastroenteritis has been confirmed by others (21) and extended to also include children with postdiarrheal hemolytic-uremic syndrome (HUS) (22). In some cases, serum uric acid levels in HUS exceed 20 mg/dl (200 mg/liter, or more than 3 times the upper limit of normal), leading to speculation that urate nephropathy might add insult to the injury induced by Shiga toxin itself (23). In virtually all of the reports of hyperuricemia in infectious gastroenteritis, the authors were at a loss to explain the mechanism of the increased uric acid levels except to invoke possi-ble “oxidative stress responses.” A pathogenic feature common between EPEC, STEC, rotavirus, and non-Typhi Salmonella infections is lytic damage to enterocytes, resulting in liberation of intracellular contents into the intestinal lumen. ATP, DNA, and RNA released into the lumen would be broken down by nucleases and nucleotidases normally present in the intestine and generate uric acid that can be reabsorbed into the bloodstream. We believe that our data provide a cell biological mechanism for the hyperuricemia that has been often observed, but not well explained, over the past decades. Serum uric acid levels should be measured more often in infectious diarrheal illness, since this inexpensive test may provide a clue to the etiologic agent responsible.

Xanthine oxidase has been widely recognized as a key host defense molecule over many decades (24), but its protective role has been best studied in milk and lactation (1, 3, 8), with much less research on the role of endogenous intestinal XO after weaning (25, 26). XO is more abundant in milk than in any other tissue or body fluid and is at especially high levels in colostrum and early milk (3). Members of the Enterobacteriaceae (including E. coli strains such as EPEC and STEC) and Salmonella enterica are more resistant to killing by XO than other bacteria (Fig. 4) (27). Other research groups have noted the potent effects of H2O2 on STEC virulence but assumed that the H2O2 derives from the NADPH oxidase of neutrophils (4, 5). In contrast to neutrophils, which must be recruited to the intestinal lumen in response to infection, XO is constitutively expressed in intestinal epithelial cells (2). Therefore, it is reasonable to think that H2O2 generated via XO may appear more quickly after infection than that produced by the neutrophil respiratory burst.

The role of XO-generated H2O2 as a potential mediator of a fluid secretory response in the intestine has not received much attention in the microbial pathogenesis field despite reports in the physiology literature (14, 28). H2O2 joins ATP and adenosine as the third identified soluble mediator produced in response to EPEC and STEC infection which is capable of stimulating chloride and fluid secretion in intestinal cells.

It appears unlikely that the levels of XO present in the intestine or released in response to infection are sufficient to curtail EPEC and STEC growth. Instead of killing STEC, hydrogen peroxide generated by XO appears to be a signal that the pathogen can use to sense the presence of the host and to upregulate its virulence. Molecules produced and released by the host, such as ethanol-amine (29), norepinephrine (30), and adenosine (11), are increasingly recognized as potent regulators of pathogen virulence. XO and its enzymatic product H2O2 appear to qualify as such interkingdom signals.

While XO appears not to be able to generate sufficient H2O2 to kill pathogenic E. coli, it may produce enough to seriously perturb the normal microbiota, especially anaerobic and microaerophilic microbes (Fig. 4C). The anaerobic microbiota of the gut, and of B. thetaiotaomicron in particular, secretes soluble factors that inhibit Stx production (31). Elimination of anaerobic microbes via H2O2 would be another mechanism by which XO regulates virulence.

Because of the many possible deleterious effects of XO activity shown in this report (Fig. 4 to 7), one wonders if the intermediate amounts of XO activity present in the intestine leave the host in a worse condition than if there were no XO at all. Is having a little bit of XO activity, like a little bit of knowledge, a dangerous thing? Figure 7 questions whether, in the context of infection with EPEC and STEC, there is a danger zone in the middle range of XO ex-
pression in the gut. If so, intermediate amounts of XO activity might place host defenses in an “uncanny valley” in which the outcome would be worse than that at either extreme. The concept of the uncanny valley was proposed by Masahiro Morii, computer scientist and roboticist, in a prescient essay in 1970 (32). In Fig. 7, the term uncanny valley is being used not to refer to a human-like robot but in the way that a familiar host defense system, xanthine oxidase, suddenly seems unfamiliar and strange in light of new data. If an uncanny valley does exist for XO, a disease other than EPEC and STEC infection for which the valley might manifest itself is necrotizing enterocolitis (NEC), a serious gastrointestinal condition that occurs in premature newborns. Xanthine oxidase has been suggested as a contributing factor in the pathogenesis of this multifactorial condition (33). Human and animal trials for NEC provide support for interventions to both inhibit XO activity (administering allopurinol) (34) and increase XO activity, such as early introduction of human milk (35). Administration of probiotics in NEC is another intervention which would make sense in light of Fig. 4C.

The results of this paper should not be construed as a criticism of breastfeeding, especially in areas of high diarrhea prevalence. The data in support of breastfeeding being protective against enteric and diarrheal pathogens are very strong, and breast milk contains many antimicrobial factors in addition to xanthine oxidase, including immunoglobulins, lactoferrin, and a vast array of oligosaccharides with antimicrobial effects (36).

In summary, XO appears to have signaling functions in the intestine that may be just as important as the host defense properties emphasized in earlier reports and reviews. Understanding the role of XO might help devise strategies to prevent or treat the severe complications of STEC infection, a subject that has been of interest to us and others (6).

ACKNOWLEDGMENTS

We thankfully acknowledge the financial support of the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), through grants ROI AI 081528 and R21 AI 102212.

REFERENCES

1. Hancock J, Salisbury V, Ovejero-Boglione M, Cherry R, Hoare C, Eisenthal R, Harrison R. 2002. Role of xanthine oxidase as an antimicrobial agent. Infect. Immun. 70:4933–4939.
2. Stevens C, Millar T, Clinch J, Kanczler J, Bodamyali T, Blake D. 2000. Antibacterial properties of xanthine oxidase in human milk. Lancet 356:829–830.
3. Müller T, Clinch J, Kanczler J, Bodamyali T, Blake D. 2000. Antibacterial properties of xanthine oxidase in human milk. Lancet 356:829–830.
4. Wagner PL, Acheson DWK, Waldo MK. 2001. Neutrophils and their products induce Shiga toxin production by enterohemorrhagic Escherichia coli. Infect. Immun. 69:1934–1937.
5. Los MJ, Los M, Wegrzyn A, Wegrzyn G. 2010. Hydrogen peroxide-mediated induction of the Shiga toxin-converting lambdoid prophage ST2-8624 in Escherichia coli O157:H7. FEMS Microbiol. Lett. 30(3):322–329.
6. Crane JK, Byrd IW, Boedeker EC. 2011. Virulence inhibition by zinc in Shiga-toxigenic Escherichia coli. Infect. Immun. 79:1696–1705.
7. Crane J, Shulgina I, Naether T. 2007. E. coli: A whole organism secretion of enteropathogenic Escherichia coli. Purinergic Signal. 3:233–246.
8. Harrison R. 2006. Milk xanthine oxidase: properties and physiological roles. Int. Dairy J. 16(5):546–554.
9. Crane J, Choudhari S, Naether T, Dufrey M. 2006. Mutual enhancement of virulence by enterotoxigenic and enteropathogenic Escherichia coli. Infect. Immun. 74:1505–1515.
35. Sisk P, Lovelady C, Dillard R, Gruber K, O'Shea T. 2007. Early human milk feeding is associated with a lower risk of necrotising enterocolitis in very low birth weight infants. J. Perinatol. 27:428–433.

36. Morrow AL, Ruiz-Palacios GM, Altaye M, Jiang X, Lourdes Guerrero ML, Meinzen-Derr JK, Farkas T, Chaturvedi P, Pickering LK, Newburg DS. 2004. Human milk oligosaccharides are associated with protection against diarrhea in breast-fed infants. J. Pediatr. 145(3):297–303.

37. Levine M, Nalin D, Hornick R, Bergquist E, Waterman D, Young C, Sotman S, Rowe B. 1978. Escherichia coli strains that cause diarrhea but do not produce heat-labile or heat-stable enterotoxins and are not invasive. Lancet i:1119–1122.

38. Rothbaum R, McAdams A, Giannella R, Partin J. 1982. A clinicopathologic study of enterocyte-adherent Escherichia coli: a cause of protracted diarrhea in infants. Gastroenterology 83:441–454.

39. Puente JL, Bieber D, Ramer SW, Murray W, Schoolnik GK. 1996. The bundle-forming pili of enteropathogenic Escherichia coli: transcriptional regulation by environmental signals. Mol. Microbiol. 20:87–100.

40. Jerse A, Yu J, Tall B, Kaper J. 1990. A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proc. Natl. Acad. Sci. U. S. A. 87:7839–7843.

41. Meselson M, Yuan R. 1968. DNA restriction enzyme from E. coli. Nature 217:1110–1114.

42. Perna NT, Plunkett G, Burland V, Mau B, Glasner JD, Rose DJ, Mayhew GF, Evans PS, Gregor J, Kirkpatrick HA. 2001. Genome sequence of enterohaemorrhagic Escherichia coli O157: H7. Nature 409:529–533.

43. Milon A, Oswald E, De Rycke J. 1999. Rabbit EPEC: a model for the study of enteropathogenic Escherichia coli. Vet. Res. 30:203–219.